While in the secondary analysis, the fewer conservative but clinically meaningful criterion of steady reaction (described for a 50% or more reduction in MADRS from baseline for 2 months) was used. With the patients who attained secure response, twenty five.8% during the esketamine group and 57.6% within the placebo group https://davidy222xmb1.gigswiki.com/user